Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate through funding granted by the BioInovation institute (Novo Nordisk Foundation) and plan to begin first-in-human trials by 2023.

The company has identified and patented a new class of proprietary ligands that share a pharmacological profile with psilocybin, which has shown promising clinical results in the treatment of depression.

Lophora is currently focusing on Treatment-Resistant Depression, but clinical data suggests that the new drug class will be applicable to the treatment of other CNS disorders including anxiety, PTSD and substance abuse.

Lophora holds a unique position in the market for anti-depressant therapies of the future. The company has qualified lead-candidate LPH-5 through pre-clinical operations, expecting IND status by the end of Q1 2023.

Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards Psychedelic-assisted therapy as a treatment for CNS disorders.